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Abstract
Background: The widespread use of empiric broad spectrum antibiotics has contributed to the global increase of
Resistant Gram-Negative Bacilli (RGNB) infections in intensive care units (ICU). The aim of this study was to develop
a tool to predict nosocomial RGNB infections among ICU patients for targeted therapy.
Methods: We conducted a prospective observational study from August’07 to December’11. All adult patients who were
admitted and stayed for more than 24 hours at the medical and surgical ICU’s were included. All patients who developed
nosocomial RGNB infections 48 hours after ICU admission were identified. A prediction score was formulated by using
independent risk factors obtained from logistic regression analysis. This was prospectively validated with a subsequent
cohort of patients admitted to the ICUs during the following time period of January-September 2012.
Results: Seventy-six patients with nosocomial RGNB Infection (31bacteremia) were compared with 1398 patients with
Systemic Inflammatory Response Syndrome (SIRS) without any gram negative bacterial infection/colonization admitted to
the ICUs during the study period. The following independent risk factors were obtained by a multivariable logistic
regression analysis - prior isolation of Gram negative organism (coeff: 1.1, 95% CI 0.5–1.7); Surgery during current admis-
sion (coeff: 0.69, 95% CI 0.2–1.2); prior Dialysis with end stage renal disease (coeff: 0.7, 95% CI 0.1–1.1); prior use of
Carbapenems (coeff: 1.3, 95% CI 0.3–2.3) and Stay in the ICU for more than 5 days (coeff: 2.4, 95% CI 1.6–3.2). It
was validated prospectively in a subsequent cohort (n = 408) and the area-under-the-curve (AUC) of the GSDCS
score for predicting nosocomial ICU acquired RGNB infection and bacteremia was 0.77 (95% CI 0.68–0.89 and 0.78
(95% CI 0.69–0.89) respectively. The GSDCS (0–4.3) score clearly differentiated the low (0–1.3), medium (1.4–2.3)
and high (2.4–4.3) risk patients, both for RGNB infection (p:0.003) and bacteremia (p:0.009).
Conclusion: GSDCS is a simple bedside clinical score which predicts RGNB infection and bacteremia with high
predictive value and differentiates low versus high risk patients. This score will help clinicians to choose
appropriate, timely targeted antibiotic therapy and avoid exposure to unnecessary treatment for patients at low
risk of nosocomial RGNB infection. This will reduce the selection pressure and help to contain antibiotic
resistance in ICUs.
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Background
The increase of drug resistant bacteria worldwide has
caused concern amongst healthcare professionals and the
wider community [1]. In particular, the increase in resist-
ance among gram negative bacteria over the last decade,
has been described as “Bad Bugs, No Drugs” by the Infec-
tious Diseases Society of America [2]. This issue was the
key component for the World Health Organization’s
World Health Day 2011 [3] and major public health action
plans have been formulated by international agencies in-
cluding the United States Centres for Disease Control and
Prevention [4] and Public Health England [5].
With their altered bacterial flora, impaired immune re-
sponse and breached anatomical integrity due to invasive
procedures and devices, the intensive care unit (ICU)
population is among the highest incidences of nosocomial
infections [6,7]. Many of these nosocomial infections are
due to drug resistant bacteria [8] with an increasing pre-
dominance of gram negative organisms [9-11]. Surveil-
lance studies across the world have demonstrated an
increase in resistance among gram negative organisms es-
pecially among critically ill patients [12,13]. In our local
setting, third generation cephalosporin-resistant gram
negative bacteria (GNB) were found to be the most com-
mon organisms among ICU isolates [14].
With few new antibiotics in the pipeline, the emphasis
has been on prevention and control of the spread of resist-
ant gram negative bacilli (RGNB) [15]. Effective infection
control practices, surveillance measures, antimicrobial
stewardship programs [16-18] have been implemented to
attempt to reduce the occurrence of nosocomial RGNB
infections. Widespread inappropriate use of antibiotics in
the hospital [19,20] and ICU [21] is common. This, in
addition to the presence of invasive devices, surgical pro-
cedures and severe co-morbid conditions are risk factors
for RGNB infection and colonization [22-25]. Unfortu-
nately, heterogeneity of cohorts, restricted number of risk
factors studied and relatively small sample sizes have lim-
ited the applicability of many previous studies to direct
clinical practice. We believe that it would be useful for cli-
nicians to use these risk factors as an objective bedside
tool to start empiric broad-spectrum antibiotic in highly
susceptible critically ill patients and avoid antibiotic over-
exposure in those at low risk.
In the current study, using clinical, demographic and
therapeutic observations, we aim to develop a simple
bedside prediction tool for nosocomial RGNB infection
in the ICU, in order to help clinicians with selection of
empiric antibiotics for patients with SIRS on admission.
Methods
Setting
This is a prospective observational cohort study conducted
over a period of 4.5 years (August’07- December’11)
followed by nine month validation period from January-
September’12 at a 1000-bedded tertiary academic medical
centre affiliated to the National University of Singapore. All
patients aged more than 21 years admitted to the medical
and surgical ICUs and stayed for more than 24 hours were
included in the study. The Medical ICU (MICU) is a 12
bed unit which admits all patients under the care of in-
ternal medicine teams including hematology-oncology
but excluding cardiology. The Surgical ICU (SICU) is a
13 bed unit which admits all elective and emergency
surgical patients excluding cardiothoracic surgery. Both
units are managed by trained intensivists with nursing
ratio varying from 1:1 to 1:2 and follow strict infection
control practices including WHO recommended hand-
hygiene guidelines [26].
Data collection
A hospital-wide computerized database (Computerized Pa-
tient Support System, CPSS, Singapore) [27] that collects
the electronic medical records, including discharge sum-
maries and biochemical, hematological, microbiological
and radiological investigations, was accessed to record the
following data prospectively: demographics, comorbidities,
Acute Physiology and Chronic Health Evaluation II (APA-
CHE II) scores on the day of admission to the ICU, surgical
interventions, prior hospital admission within one year
from the current admission, results of Methicillin-resistant
Staphylococcus aureus (MRSA) screening on admission to
the ICU, antibiotics usage and, culture and sensitivity of
the clinical isolates. For all patients included in the study,
detailed antibiotic prescription history was obtained by
reviewing their previous electronic records and outpatient
medications. The data were collected in a palmtop device
using HanDBase4 Database manager (Wellington, FL,
USA) and stored in MS Access database for further ana-
lysis. All clinical and microbiological details for each pa-
tient including the first isolation of GNB from any clinical
specimen during the patient’s stay in the ICU were re-
corded. Patients who had a GNB isolated from any of the
cultures within 48 hours of admission to the ICU were ex-
cluded from the analysis.
Definitions
Resistant gram negative bacilli (RGNB)
Acinetobacter baumannii, Pseudomonas aeruginosa,
Klebsiella pneumoniae, Escherichia coli: Multi-drug re-
sistance was defined as being non susceptible to > = 1 agent
in > = 3 antimicrobial categories. The antimicrobial categor-
ies were counted independently for each organism [28].
Colonization
Those patients with RGNB/SGNB cultured from any
clinical specimen with no clinical signs or symptoms of
infection and no treatment initiated or changed by the
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treating clinician or documented as colonization by the
Infectious disease specialist [29].
Infection
All patients with RGNB/SGNB cultured from any of the
clinical specimens and an infection was documented by
the clinicians with initiation or change of treatment for
the organism. The criteria for infection are similar to
those used by the United States National Health and
Safety Network [29]. For those patients with a positive re-
spiratory culture, the quality of the clinical specimen was
assessed by calculating the Q score [30] and those positive
specimens with unacceptable Q scores were considered to
be colonizers. We also calculated the CPIS scores for
those patients with acceptable Q scores and only those
with a CPIS score of more than 6 were considered to be
nosocomial pneumonia [31]. All those patients with con-
firmed urinary tract infection in our study had more than
103 CFU/ml reported in their culture results.
Nosocomial RGNB infection in the ICU
RGNB isolated after 48 hours of admission to the ICU.
SIRS
SIRS was confirmed if the patient satisfied 2 or more
standard criteria [32].
Statistical analysis
Analysis was done using STATA 10.1 (STATA Corp,
Texas, USA). Patients with nosocomial ICU acquired
RGNB infections were compared with SIRS patients who
had no GNB isolated during their ICU stay.
Univariate analysis was done including all the potential
risk factors using Chi-square/Fisher’s exact tests for com-
paring proportions and Student’s t test/Wilcoxon rank
sum tests for continuous variables where applicable.
Identification of Independent Risk Factors: Those risk
factors with a p ≤ 0.05 in univariate analysis were then
included in the forward step wise multivariable logistic
regression analysis. The discriminatory power of this
derivation model was tested using receiver operating
curve (ROC) analysis [33] by assessing the area under
the curve (AUC) and the calibration efficiency was
tested using Hosmer Lemeshow test [34]. Potential inter-
actions were also checked in the prediction model.
Score Formulation: A score was then calculated by
assigning points based on the regression coefficients ob-
tained from the logistic regression analysis for the inde-
pendent risk factors associated with the occurrence of
nosocomial RGNB infection in the ICU.
Prospective validation: The scores were applied to a
separate cohort of patients admitted to the ICUs from
January–September 2012. A receiver operating characteris-
tic analysis and area under the curve (AUC) was obtained.
Assessment of the score in patients with bacteremia:
We tested the score in a subset of RGNB infection with
bacteremia using the ROC analysis.
The study was approved by the National Healthcare
Group (NHG) Domain Specific Review Board that gov-
erns research at our institution (Reference: B/06/140).
Results
Two thousand nine hundred and forty nine patients who
stayed for more than 24 hours in the ICU’s were in-
cluded in our study. The details of the patients included
for the analysis are shown in Figure 1. Excluding the pa-
tients who had a GNB before or within 48 hours of ad-
mission to the ICU and those patients with a SGNB
during the hospital stay, 1927 patients were included in
the derivation cohort. 1474 (76.5%) patients satisfied the
criteria for SIRS on admission to the ICU and were in-
cluded in the risk factor analysis. There were 76 patients
with nosocomial RGNB infections in the ICU. The ma-
jority of these RGNB infections were bacteremias
(40.8%) followed by pneumonia (27.6%) and urinary tract
infections (11.8%). Sixteen (22.8%) were polymicrobial
RGNB infections and 9 (12%) were polymicrobial bacter-
emias. The patients with polymicrobial infections were
counted as a single infection for the analysis. Table 1
shows the patients characteristics of those with RGNB
infection and without GNB infection/colonization.
Identification of independent risk factors
By including the risk factors with a p ≤0.05 from the
univariate analysis (Table 1) in a forward logistic regres-
sion analysis, we obtained the independent risk factors
for nosocomial RGNB infection (Table 2). This predic-
tion model had a hosmer-lemeshow fit of 0.63 and an
area under the curve of 0.80 (95% CI: 0.75–0.85).
Score formulation
Based on the regression coefficients from the logistic re-
gression (Table 2), we formulated the GSDCS (Gram
Negative bacteria in last 6 months, Surgery during
current admission before RGNB, prior Dialysis with end
stage renal disease, prior use of Carbapenem within last
6 months, Stay in the ICU for more than 5 days) score
by allotting the points as follows: 1 point each for pres-
ence of prior GNB and prior administration of carbapen-
ems within 6 months, 0.6 points for surgery before
RGNB, 0.7 points for dialysis with end stage renal dis-
ease and 2 points for a stay of more than 5 days in the
ICU. All these individual points were added up to
achieve the score. In order to factor in the interaction, a
score of −1 was added for all those patients who had
stayed for more than 5 days in the ICU with prior ex-
posure to Carbapenem to obtain the final score for pre-
diction of nosocomial RGNB infection in the ICU. The
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sensitivity and specificity values at the different cut-off
points are shown in Table 3. The patients were then seg-
regated into low (0–1.3 points), medium (1.4–2.3 points)
and high risk (2.4–4.3 points) categories based on their
scores. The prevalence of RGNB infection among the
three groups in the increasing order were 1.2%, 6.3% and
19.8% respectively (p < 0.001).
There were 31 (40.8%) patients with bacteremia
among the patients with RGNB infections. The GSDCS
score yielded an AUC of 0.83 (95% CI 0.76–0.89) when
applied to bacteremic patients. The prevalence of RGNB
bacteremia in the low, medium and high risk categories
was 0.2%, 3% and 9.7% respectively (p < 0.001).
Prospective validation
The score was then applied to a new cohort of patients
admitted to both the ICUs from January – September
2012. Similar to the derivation cohort, we excluded all
those patients with a positive GNB culture before or
within 2 days of ICU admission. There were 483 patients
who were admitted during the validation period and 64
of them had a GNB isolated before or within 48 hours of
admission to the ICU and were excluded from the ana-
lysis. Of the remaining 419 patients, 408 satisfied the cri-
teria for SIRS and were included in the validation
cohort. 18 of these 408 patients had nosocomial ICU ac-
quired RGNB infection. The GSDCS score yielded an
AUC of 0.77 (95% CI 0.68–0.89) for prediction of noso-
comial RGNB infection in the ICU (Figure 2A). The
prevalence of RGNB infections among patients with low,
medium and high risk categories were 1.7%, 6.3% and
12% respectively (p0.003) (Figure 2B). Eleven (61.1%) of
the validation cohort with RGNB infections had
bacteremia. The GSDCS score yielded an AUC of 0.78
(95% CI 0.69–0.89) when applied to predict RGNB
bacteremia among this cohort (Figure 3A). The preva-
lence of RGNB bacteremia was 0.9%, 4% and 8% among
the low, medium and high risk categories (p 0.009)
(Figure 3B).
Discussion
In our setting, prior isolation of any GNB, receipt of car-
bapenems in the previous 6 months, surgery, patients
with end stage renal disease undergoing dialysis and
those with an ICU stay of more than 5 days were associ-
ated with a higher risk of contracting an RGNB infection
in the ICU. We found that a negative interaction existed
between carbapenem administration and a stay of more
than 5 days in the ICU. In our cohort, we found that
end stage renal failure on dialysis was more important
than the overall APACHEII score in the multivariable
analysis. This is similar to others who have found that
APACHE II score does not necessarily predict the risk of
infection with multi-drug resistant organisms in the ICU
[23,35] Based on the risk factors identified, we formu-
lated the bedside GSDCS score (0–4.3) in line with
Wasson et al. [36].
When applied to the validation cohort of patients from
same ICUs, the score yielded AUC’s of 0.77 and 0.78 for
RGNB infection and bacteremia respectively. The score
was able to clearly segregate the low from high risk pa-
tients, for both RGNB infection and bacteremia.
With their reduced immune status and increased anti-
biotic usage in ICUs, critically ill patients are vulnerable
Figure 1 Patient flowchart.
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Table 1 SIRS patients- Nosocomial ICU acquired RGNB Infection and patients with no GNB: Patient characteristics and
univariate analysis
No GNB* Infection/colonization (n = 1398) RGNB† Infection (n = 76) p-value
Gender, n (%) 0.49
Male 902 (64.5%) 52 (68.4%)
Female 496 (35.5%) 24 (31.6%)
Age, years (mean, ±SD) 56.9 (SD17.8) 59.7 (SD17.6) 0.19
APACHEII‡ (median, range) 17 (1–55) 19 (2–39) 0.03
Intensive care unit, n (%) 0.02
Medical 868 (62.9%) 37 (49.3%)
Surgical 513 (37.1%) 38 (50.7%)
Comorbidities, n (%)
Diabetes Mellitus 427 (30.5%) 24 (31.6%) 0.85
Dialysis with end stage renal disease 130 (9.3%) 14 (18.4%) 0.009
Peripheral vascular disease 25 (1.8%) 0 (0%) 0.24
Cerebrovascular accident 207 (14.8%) 8 (10.5%) 0.3
Peptic ulcer disease 67 (4.8%) 4 (5.3%) 0.85
Myocardial Infarction 178 (12.7%) 10 (13.2%) 0.91
Congestive cardiac failure 48 (3.4%) 4 (5.3%) 0.4
Liver disease 52 (3.7%) 3 (3.9%) 0.92
Leukemia 34 (2.4%) 4 (5.3%) 0.13
Malignancy 163 (11.7%) 9 (11.8%) 0.96
Procedure/treatment, n (%)
Mechanical ventilation 1310 (93.7%) 75 (98.7%) 0.08
Duration of mechanical ventilation 4.5 (SD 4.02) 7.5 (SD 4.9) 0.01
Central venous catheter 920 (65.8%) 58 (76.3%) 0.05
Intra-arterial line 1113 (79.6%) 65 (89.5%) 0.21
Urinary catheter 1156 (82.7%) 70 (92.1% 0.04
Surgery this admission before RGNB 524 (37.5%) 42 (55.3%) 0.002
Transfusion 411 (29.4%) 35 (46.1%) 0.02
Sedation 982 (81%) 67 (91.8%) 0.02
Carbapenems within 6 months 409 (29.3%) 39 (51.3%) <0.001
3rdGeneration Cephalosporins within 6 months 721 (51.6%) 34 (44.7%) 0.25
Other Cephalosporins within 6 months 200 (14.3%) 17 (22.7%) 0.05
Quinolones within 6 months 248 (17.7%) 17 (22.7%) 0.28
Penicillins within 6 months 385 (27.5%) 29 (38.7%) 0.04
Aminoglycosides within 6 months 92 (6.6%) 11 (14.7%) 0.007
Augmentin/Unasyn within 6 months 615 (43.9%) 24 (32%) 0.04
Other antibiotics within 6 months 790 (56.5%) 52 (69.3%) 0.03
Hospitalization in the past one year 246 (17.6%) 19 (25%) 0.1
Median days of pre-ICU stay in the hospital (range) 0 (0–40) 0 (0–29) 0.05
Days of stay in ICU >5 444 (31.8%) 59 (77.6%) <0.001
Cultures, n (%)
Positive MRSAll screening on admission to ICU 69 (5.4%) 5 (7.1%) 0.53
Presence of any GNB within 6 months 102 (7.3%) 23 (30.3%) <0.001
*Gram negative bacteria, †Resistant gram negative bacteria, ‡Acute Physiology and Chronic Health Evaluation, llMethicillin-resistant Staphylococcus aureus.
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to nosocomial infections [37]. The American Thoracic
Society guideline [38] recommends early and appropriate
use of antibiotics to reduce morality in hospital acquired
infections. Delayed initiation of appropriate antibiotics
[39] or changing the antibiotics based on the susceptibility
results available later in the course of treatment [40,41]
may be associated with increased mortality among pa-
tients with hospital acquired pneumonia. Given the press-
ing need to get the antibiotic treatment “right the first
time, every time and without delay”, the broadest
spectrum antibiotics have become the first line of therapy
for nosocomial infections in many modern ICUs. A study
involving 43 Italian ICUs showed that 75% of ICU patients
without sepsis received antibiotics with no reason identi-
fied for 20% of them and “prophylaxis” as the reason in
the majority [42]. This leads to widespread, over-usage of
antibiotics with concomitant “collateral damage” in terms
of selection of resistant organisms. In this context, we have
shown before that even a short duration of carbapenem
use in critically ill patients increases the risk of infection
or colonization with multidrug resistant bacteria [43]. At
the same time, inadequate definitive antimicrobial therapy
is consistently associated with increased mortality in critic-
ally ill patients mainly due to the presence of resistant
Table 2 Nosocomial ICU acquired RGNB* Infection: Independent risk factors- logistic regression (Comparison with SIRS
patients with no GNB† Infection/Colonization)
Nosocomial ICU acquired RGNB infection Coef. P > z 95% Conf. interval
Days of stay in ICU >5 2.37 <0.001 1.56 3.18
Carbapenems within 6 months 1.32 0.008 0.34 2.30
Presence of any GNB within 6 months 1.14 <0.001 0.58 1.70
Dialysis with end stage renal disease 0.79 0.017 0.14 1.45
Surgery this admission before RGNB 0.69 0.005 0.21 1.19
Interaction: Carbapenems *days in ICU > 5 −1.42 0.013 −2.55 −0.30
_cons −5.02 <0.001 −5.78 −4.26
*Resistant gram negative bacteria, †Gram negative bacteria.
Table 3 Sensitivity and Specificity values of the scores
Cutpoint Sensitivity Specificity Correctly classified LR+ LR-
(> = 0) 100.00% 0.00% 5.16% 1
(> = .6) 94.74% 28.97% 32.36% 1.3338 0.1817
(> = .7) 92.11% 48.64% 50.88% 1.7934 0.1623
(> = 1) 92.11% 51.79% 53.87% 1.9104 0.1524
(> = 1.3) 86.84% 59.87% 61.26% 2.1641 0.2198
(> = 1.6) 85.53% 61.02% 62.28% 2.1939 0.2372
(> = 1.7) 69.74% 72.39% 72.25% 2.5257 0.4181
(> = 2) 68.42% 73.89% 73.61% 2.6206 0.4274
(> = 2.2) 60.53% 82.62% 81.48% 3.4821 0.4778
(> = 2.3) 52.63% 87.41% 85.62% 4.1806 0.5419
(> = 2.6) 51.32% 88.70% 86.77% 4.5405 0.5489
(> = 2.7) 32.89% 95.35% 92.13% 7.0749 0.7038
(> = 2.9) 28.95% 96.35% 92.88% 7.935 0.7374
(> = 3) 25.00% 96.92% 93.22% 8.1279 0.7738
(> = 3.2) 22.37% 97.78% 93.89% 10.0874 0.7939
(> = 3.3) 13.16% 98.78% 94.37% 10.8204 0.8791
(> = 3.6) 9.21% 99.21% 94.57% 11.7057 0.9151
(> = 3.9) 2.63% 99.79% 94.78% 12.2632 0.9758
(> = 4.3) 0.00% 99.93% 94.78% 0 1.0007
(>4.3) 0.00% 100.00% 94.84% 1
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organisms [44]. There is therefore a critical need to iden-
tify, at the bedside, which patients are at highest risk for
nosocomial infection with multi-drug resistant pathogens
so that initial empiric therapy can be targeted at these pa-
tients without adversely affecting the rest of the patients
in the ICU.
Unfortunately, many previous studies which identified
risk factors for RGNB in ICU [22,23,45-47] were either
limited by their retrospective study design or by focusing
on specific bacteria, drugs or groups of patients. Further,
without aggregating these risk factors, the utility of this
information at the bedside is limited. Comprehensive de-
cision analysis tools and scoring systems have been
employed to overcome some of these issues. One such
widely used tool is the clinical pulmonary infection score
(CPIS) proposed by Pugin et al. for Ventilator Associated
Pneumonia although not specifically targeting antibiotic
resistant pathogens [48]. With the limitations of any de-
cision analysis tool, CPIS has been used for prognostica-
tion [49] and most importantly, to reduce indiscriminate
antibiotic usage [50]. Among patients with health-care
associated pneumonia, Shorr AF et al. developed a pre-
diction tool using 4 criteria to identify patients with
higher risk of acquiring antibiotic resistant bacteria –
these include recent hospitalization, nursing home resi-
dence, hemodialysis and ICU admission [51]. Similarly, a
prediction tool was developed for predicting multidrug re-
sistance in P.aerugionsa [52] among patients with respira-
tory tract infections using a case control methodology.
Although informative, neither was able to generate a com-
prehensive validated scoring system for RGNB infection/
bacteremia which could be applied at the bedside in the
ICUs. Since application of clinical evidence varies tremen-
dously amongst clinicians [53], use of a simple scoring sys-
tem would help narrow the variability between clinicians in
decision making especially in the complex ICU setting.
Our GSDCS score is easy to apply and may help clini-
cians in ICU to identify the patients at risk of RGNB infec-
tion and bacteremia who need early broad-spectrum
appropriate antibiotics while reducing the risk of unneces-
sary antibiotic exposures. Striking this balance will be cru-
cial to reduce the emergence of antimicrobial resistance
while averting mortality from nosocomial infections.
Strengths of this current study include the use of readily
available bedside information to formulate the GSDCS
score. The prospective validation of the score using a separ-
ate cohort indicated that score was indeed robust in pre-
dicting a nosocomial drug resistant gram negative infection.
This study is a prospective observational cohort study and
all the patients were followed up diligently until their dis-
charge from the hospital. No changes were instituted in the
treatment plan as this study was conducted by a research
Figure 2 Performance of GSDCS score in predicting nosocomial RGNB infection. A: Receiver Operating Characteristics. B: Prevalence by
risk categories.
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assistant independent of the treating team. However,
our study also had some limitations. This was a single
centre study and further validation needs to be done in
other settings. We also excluded patients who had
RGNB cultured before or with 48 hours of ICU admission
to capture our primary outcome of interest - patients
who developed ICU acquired nosocomial infections.
Because of this, our numerator was relatively small in
spite of screening a very large number of ICU admis-
sions. There was no routine screening done for RGNB
during the study period as unlike MRSA, there are no
universally accepted screening methods for RGNB. We
were also unable to obtain the comprehensive past
antibiotic history of those patients with previous
admission to different hospital systems if any.
Conclusion
This simple prospectively validated risk stratification
score for prediction of nosocomial RGNB infection and
bacteremia will help the clinicians to identify critically ill
patients who are at risk of antibiotic resistant gram-
negative infections. This should logically lead to targeted
antibiotic treatment while avoiding antibiotic overuse
which worsens the vicious cycle of resistance in the ICU.
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